Evidence map›Paper›PMID 41639022›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2026

Differences in blood levels of neuroligin-derived peptides in a cohort for early detection of Alzheimer's disease.

Milton G F Fernandes, Maxime Pinard, Esen Sokullu, Cyntia Tremblay, Jean-François Gagnon, Frédéric Calon, Benoit Coulombe, Jonathan Brouillette

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Milton G F FernandesDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.ORCID 0000-0002-1536-5083
Maxime PinardTranslational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Québec, Canada.
Esen SokulluTranslational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Québec, Canada.
Cyntia TremblayNeuroscience Axis CHU de Québec Research Center, Laval University, Quebec City, Québec, Canada.
Jean-François GagnonDepartment of Psychology, Université du Québec à Montréal, Montreal, Québec, Canada.
Frédéric CalonNeuroscience Axis CHU de Québec Research Center, Laval University, Quebec City, Québec, Canada.
Benoit CoulombeTranslational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Québec, Canada.
Jonathan BrouilletteDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Québec, Canada.

Funding

Weston Brain Institute RR192181
6 · The paper itself

Abstract

Alzheimer's disease (AD) develops gradually, with significant neurodegeneration already present by the time clinical symptoms emerge. Since synapses are affected early in the disease, synaptic proteins are being investigated as potential markers of the prodromal stage. Using data and plasma samples provided by the Consortium for the early identification of Alzheimer's disease-Quebec, we analyzed plasma levels of neuroligin (NLGN)-derived peptides in cognitively normal (CN) individuals and cognitively impaired (CI) individuals, including those with amnestic mild cognitive impairment and early-stage AD. Plasma levels of NLGN-derived peptides were assessed by quantifying tryptic peptides using liquid chromatography coupled with tandem mass spectrometry. Our findings show that levels of specific NLGN peptides were significantly elevated in CI compared to CN individuals. Receiver operating characteristic curve analysis revealed that some NLGN peptides could distinguish CI individuals. Furthermore, analysis based on mini-mental state examination scores revealed that specific plasma phosphorylated tau peptides were significantly and positively correlated with selected NLGN-derived peptides in more advanced stages of cognitive decline. These results support further investigation into synaptic NLGN-derived peptides in the blood as promising tools for monitoring the earliest stages of AD.

Indexed as

Alzheimer DiseaseCell Adhesion Molecules, NeuronalNeuroliginsAgedAged, 80 and overBiomarkersCognitive DysfunctionEarly DiagnosisFemaleHumansMaleROC Curvetau ProteinsBiomarkersCell Adhesion Molecules, NeuronalNeuroliginstau ProteinsCIMA-QNeurodegenerationNeuroliginSynapseTau

Identifiers

PMID41639022
PMCPMC13049705

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.